Moderna's stock has experienced significant volatility, with a recent downgrade by Wolfe Research to "Underperform".The company has secured a $1.5 billion loan from Ares Management to support up to 10% revenue growth.Despite challenges, active investor interest is reflected in a trading volume of 17.16 million shares.Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company known for its work in developing mRNA-based vaccines and therapeutics. The company gained significant attention during the COVID-19 pandem ...